Gout and the COVID-19 pandemic.
Curr Opin Rheumatol
; 34(2): 111-117, 2022 03 01.
Article
in English
| MEDLINE | ID: covidwho-2319727
ABSTRACT
PURPOSE OF REVIEW This review gives an overview of recently published articles on COVID-19 and gout. RECENT FINDINGS:
People with gout are likely to be at an increased risk of poor outcomes after COVID-19 infection due to comorbid cardiometabolic conditions. The effects of chronic hyperuricemia on trained immunity, and the hyperinflammatory state induced by gout itself may also play a role. Frequent courses of glucocorticoids for gout flares may be associated with adverse outcomes after COVID-19 infection and reduced immunogenicity to the COVID-19 vaccination. Similarities between the pathophysiology of gout flares and the dysregulated inflammatory response of severe COVID-19 have been identified. Medications used in the treatment of gout, including colchicine and interleukin-1 inhibitors, have shown promise in the treatment of COVID-19 in clinical trials. Overall, the COVID-19 pandemic has had a negative impact on gout care, with patients reporting more difficulty with disease control, accessing medications and healthcare, and poorer quality of life.SUMMARY:
The COVID-19 pandemic has created many challenges for people with gout. At present, there is a lack of guidance on the management of gout during the pandemic and paucity of research assessing outcomes of COVID-19 infection in people with gout.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hyperuricemia
/
COVID-19
/
Gout
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Curr Opin Rheumatol
Journal subject:
Rheumatology
Year:
2022
Document Type:
Article
Affiliation country:
BOR.0000000000000860
Similar
MEDLINE
...
LILACS
LIS